Generated: April 23, 2017
|Title:||Process for therapeutically modifying and resetting prolactin rhythm with a dopamine agonist|
|Abstract:||A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.|
|Inventor(s):||Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA)|
|Assignee:||The Board of Supervisors of Louisiana State University and Agricultural (Baton Rouge, LA)|
|Filing Date:||Jun 06, 1995|
|Claims:||1. A process for therapeutically modifying and resetting the prolactin rhythm of a human subject which comprises administering to a human in need of treatment, a dopamine agonist on a daily basis at an hour, in amount, and for a period sufficient that the glucose disposal effects of insulin in a human will be increased and hyperglycemia decreased. |
2. The process of claim 1 wherein the dopamine agonist is administered to the human to reduce hyperinsulinemia.